IL146845A0 - Method for down-regulating gdf-8 activity - Google Patents

Method for down-regulating gdf-8 activity

Info

Publication number
IL146845A0
IL146845A0 IL14684500A IL14684500A IL146845A0 IL 146845 A0 IL146845 A0 IL 146845A0 IL 14684500 A IL14684500 A IL 14684500A IL 14684500 A IL14684500 A IL 14684500A IL 146845 A0 IL146845 A0 IL 146845A0
Authority
IL
Israel
Prior art keywords
activity
gdf
regulating
regulating gdf
Prior art date
Application number
IL14684500A
Other languages
English (en)
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of IL146845A0 publication Critical patent/IL146845A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Eletrric Generators (AREA)
  • Debugging And Monitoring (AREA)
IL14684500A 1999-07-20 2000-07-20 Method for down-regulating gdf-8 activity IL146845A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26
PCT/DK2000/000413 WO2001005820A2 (en) 1999-07-20 2000-07-20 Method for down-regulating gdf-8 activity

Publications (1)

Publication Number Publication Date
IL146845A0 true IL146845A0 (en) 2002-07-25

Family

ID=26065065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14684500A IL146845A0 (en) 1999-07-20 2000-07-20 Method for down-regulating gdf-8 activity

Country Status (21)

Country Link
US (2) US7070784B1 (xx)
EP (1) EP1200119A2 (xx)
JP (1) JP2003506325A (xx)
KR (1) KR100750695B1 (xx)
CN (1) CN1384757A (xx)
AU (1) AU778470B2 (xx)
CA (1) CA2379852A1 (xx)
EA (1) EA005248B1 (xx)
EE (1) EE200200025A (xx)
HK (1) HK1048937A1 (xx)
HR (1) HRP20010900A2 (xx)
HU (1) HUP0201861A3 (xx)
IL (1) IL146845A0 (xx)
MX (1) MXPA01013232A (xx)
NO (1) NO20016252L (xx)
NZ (1) NZ517058A (xx)
PL (1) PL353855A1 (xx)
SK (1) SK722002A3 (xx)
TR (2) TR200400621T2 (xx)
WO (1) WO2001005820A2 (xx)
ZA (1) ZA200109901B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
EP1075272B1 (en) * 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
CA2510893C (en) * 2002-12-20 2012-07-10 Amgen, Inc. Binding agents which inhibit myostatin
MXPA05012965A (es) 2003-06-02 2006-03-09 Wyeth Corp Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello.
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
JP2007535912A (ja) * 2003-12-31 2007-12-13 シェーリング−プラウ・リミテッド 中和エピトープベースの増殖増強性ワクチン
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
JP5335239B2 (ja) 2004-09-30 2013-11-06 マイオスティン・セラピューティクス・プロプライエタリー・リミテッド ミオスタチンアイソフォーム
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
US8309068B2 (en) 2006-08-03 2012-11-13 Myostin Therapeutics Pty Ltd. Isolated polypeptides and methods of improving muscle strength
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US20140223592A1 (en) * 2011-07-06 2014-08-07 Pig Myostatin Gene Locus And Uses Thereof Pig myostatin gene locus and uses thereof
US8871209B2 (en) 2011-11-14 2014-10-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
PE20150223A1 (es) 2012-06-15 2015-02-11 Pfizer Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
WO2014039189A1 (en) 2012-08-01 2014-03-13 Mcnally Elizabeth Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
CN107771081A (zh) 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
EA202092064A1 (ru) 2018-03-01 2020-12-21 Ридженерон Фармасьютикалз, Инк. Способы изменения состава тела
CA3124415A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
SK285639B6 (sk) 1997-04-15 2007-05-03 Pharmexa A/S Modifikovaná ľudská TNFalfa molekula, DNA kódujúce takéto TNFalfa molekuly, spôsob výroby modifikovanej ľudskej TNFalfa molekuly, vakcíny obsahujúce modifikované TNFalfa molekuly a DNA a ich použitie
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
EP1038016A2 (en) * 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
KR20020026544A (ko) 2002-04-10
ZA200109901B (en) 2003-05-28
CN1384757A (zh) 2002-12-11
EA200200182A1 (ru) 2002-06-27
MXPA01013232A (es) 2005-05-24
HUP0201861A3 (en) 2004-07-28
US7056512B1 (en) 2006-06-06
NO20016252D0 (no) 2001-12-19
HRP20010900A2 (en) 2003-08-31
EE200200025A (et) 2003-04-15
EA005248B1 (ru) 2004-12-30
SK722002A3 (en) 2003-02-04
JP2003506325A (ja) 2003-02-18
HK1048937A1 (zh) 2003-04-25
HUP0201861A2 (en) 2002-09-28
NO20016252L (no) 2002-03-15
KR100750695B1 (ko) 2007-08-22
NZ517058A (en) 2004-04-30
US7070784B1 (en) 2006-07-04
CA2379852A1 (en) 2001-01-25
PL353855A1 (en) 2003-12-01
WO2001005820A2 (en) 2001-01-25
AU5967500A (en) 2001-02-05
AU778470B2 (en) 2004-12-09
TR200200133T2 (tr) 2002-05-21
WO2001005820A3 (en) 2001-07-19
EP1200119A2 (en) 2002-05-02
TR200400621T2 (tr) 2004-08-23

Similar Documents

Publication Publication Date Title
HUP0201861A2 (en) Method for down-regulating gdf-8 activity
PL349010A1 (en) Method for increasing pet activity
EP1198306A4 (en) ENCLOSURE METHOD FOR PRESERVING BIO-RENOVABILITY
IL145786A0 (en) Method for down-regulating il5 activity
GB0007871D0 (en) Method
GB9915625D0 (en) Method
GB2355455B (en) Method
IL140058A0 (en) Methods for inhibiting tef-3 activity
GB0007867D0 (en) Method
GB9915936D0 (en) Method
GB2347213B (en) Method for determining nuclease activity
HU9902898D0 (en) Method for influancing thermosensibility
HU9901405D0 (en) Method for economical gold-washing
HU9904385D0 (en) Method for akkumulator change
GB9907196D0 (en) Method
GB9909988D0 (en) Method
GB9903934D0 (en) Method
GB9905234D0 (en) Method
GB9905669D0 (en) Method
GB9906056D0 (en) Method
GB9906852D0 (en) Method
GB9908160D0 (en) Method
GB9901132D0 (en) Method
GB9908162D0 (en) Method
GB9909799D0 (en) Method